No Data
No Data
The Nikkei Average rose for the fourth day, temporarily recovering to the 40,000 yen level, but concerns arise due to the decline in Asian stocks etc.
On the 14th, the US stock market continued to rise. The Dow Jones Industrial Average closed at 43,065.22, up 201.36 points, and the Nasdaq closed at 18,502.69, up 159.75 points. Following speculation of a slight interest rate cut leading to selling pressure and buying driven by expectations of demand recovery against the backdrop of additional fiscal policies by the Chinese government, the market opened with mixed results. Subsequently, expectations for earnings of major companies provided support, pushing the market higher. Furthermore, the rise of semiconductor Nvidia pushed up the Nasdaq, leading to gains towards the end of the trading session.
The afternoon Nikkei average started 551 yen higher, with Mitsukoshi Isetan, Fujisoft, etc. rising.
[Nikkei Stock Average ・ TOPIX (Table)] Nikkei Average; 40,157.43; +551.63 TOPIX; 2,733.67; +27.47 [Afternoon Opening Summary] The afternoon Nikkei average started slightly narrowing its gains from the morning close (40,232.45 yen), with an increase of 551.63 yen to 40,157.43 yen. During lunchtime, the Nikkei 225 futures traded weakly in the range of 40,180 yen to 40,270 yen. The dollar-yen rate was around 149.60-70 yen per dollar at around 9:00 AM.
October 15th [Today's Investment Strategy]
[Fisco Selected Stock] [Material Stock] Cosmos Pharmaceuticals <3349> 7320 yen (10/11) A drugstore based in Kyushu. They announced their first quarter results. Operating profit increased by 28.8% year-on-year to 11.5 billion yen. Despite a temporary decline in profitability due to in-house competition, they carried out new store openings and expanded their store network to new business territories without hesitation. The operating profit for the fiscal year ending in May 2025 is expected to be 31.6 billion yen, a 0.3% increase from the previous period. The progress rate for the first quarter compared to the full-year forecast is 36.6%. The full-year forecast is for a slight increase in profit.
Three points to focus on in the morning session~Nikkei average recovers by 0.04 million yen but australian small/mid cap stocks are difficult to handle~
In the morning session of the 15th, it is worth paying attention to the following three points: - While the Nikkei average is recovering to 0.04 million yen, it may be difficult to handle Australian small/mid cap stocks. - Quality Plan, operating profit on 8/24 increased by 69.4 to 56.1 billion yen, with an expected decrease of 2.0% to 55 billion yen on 8/25. - Points of focus in the morning: Spot work, illegal rules in the app, guidance from the Ministry of Health, Labor, and Welfare. - Despite the Nikkei average's 0.04 million yen recovery, Australian small/mid cap stocks may be challenging to handle. The Japanese stock market on the 15th started with a gap up, with attention being paid to the Nikkei Stock Average's recovery to the 0.04 million yen mark. On the 14th
Focus on Cosmos Pharmaceuticals and Marumae, while Sansan and Ryohin Keikaku are sluggish.
In the US stock market last weekend on the 11th during the 3-day holiday in Tokyo, NY Dow rose by 409.74 points, reaching 43,065.22 dollars on the 14th, up by 201.36 points. The Nasdaq Composite Index was 60.89 points higher on the 11th, reaching 18,502.69 on the previous day with an increase of 159.75 points. Yesterday's Chicago Nikkei 225 futures in Osaka were 485 yen higher than the Osaka day session at 40,095 yen. The exchange rate is 1 dollar = 149.70-80 yen. In today's Tokyo market, the operating profit for the August 2024 fiscal year is expected to increase by 71.6%, higher than the previous estimate of 58.3%.
Ryohin Keikaku, operating profit up by 69.4% to 56.1 billion yen on August 24, financial estimates for August 25 showing a 2.0% decrease to 55 billion yen.
Ryohin Keikaku <7453> announced its financial results for the August 2024 period, with operating revenue increasing by 13.8% year-on-year to 661.677 million yen, and operating profit increasing by 69.4% to 56.135 million yen. Both operating revenue and each stage profit reached record highs. The improvement in operating gross profit margin was due to the effects of domestic price adjustments and the suppression of price reductions. For the August 2025 period, operating revenue increased by 10.9% year-on-year to 734 billion yen, while operating profit decreased by 2% to 55 billion yen.
No Data
No Data